{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:09:08Z","timestamp":1789470548348,"version":"build-2803163510"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Expansion of opioid use disorder treatment is needed, particularly in rural communities.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate technology-assisted buprenorphine (TAB) efficacy (1) over a longer period than previously examined, (2) with the addition of overdose education, and (3) among individuals residing in rural communities.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Two parallel, 24-week randomized clinical trials were conducted at the University of Vermont between February 1, 2018, and June 30, 2022. Participants were adults with untreated opioid use disorder from nonrural (trial 1) or rural (trial 2) communities. These trials are part of a programmatic effort to develop TAB protocols to improve treatment availability in underserved areas.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Within each trial, 50 participants were randomized to TAB or control conditions. Participants in the TAB group completed bimonthly visits to ingest medication and receive take-home doses via a computerized device. They received nightly calls via an interactive voice response (IVR) system, IVR-generated random call-backs, and iPad-delivered HIV, hepatitis C virus (HCV), and overdose education. Control participants received community resource guides and assistance with contacting resources. All participants received harm reduction supplies and completed monthly assessments.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was biochemically verified illicit opioid abstinence across monthly assessments. Secondary outcomes included self-reported opioid use in both groups and abstinence at bimonthly and random call-back visits, treatment adherence, satisfaction, and changes in HIV, HCV, and overdose knowledge among TAB participants.<\/jats:p><\/jats:sec>Results<\/jats:title>Fifty individuals (mean [SD] age, 40.6 [13.1] years; 28 [56.0%] male) participated in trial 1, and 50 (mean [SD] age, 40.3 [10.8] years; 30 [60.0%] male) participated in trial 2. Participants in the TAB group achieved significantly greater illicit opioid abstinence vs controls at all time points in both trial 1 (85.3% [128 of 150]; 95% CI, 70.7%-93.3%; vs 24.0% [36 of 150]; 95% CI, 13.6%-38.8%) and trial 2 (88.0% [132 of 150]; 95% CI, 72.1%-95.4%; vs 21.3% [32 of 150]; 95% CI, 11.4%-36.5%). High abstinence rates were also observed at TAB participants\u2019 bimonthly dosing visits (83.0% [95% CI, 67.0%-92.0%] for trial 1 and 88.0% [95% CI, 71.0%-95.0%] for trial 2). Treatment adherence was favorable and similar between trials (with rates of approximately 99% for buprenorphine administration, 93% for daily IVR calls, and 92% for random call-backs), and 183 of 187 urine samples (97.9%) tested negative for illicit opioids at random call-backs. iPad-delivered education was associated with significant and sustained increases in HIV, HCV, and overdose knowledge.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In these randomized clinical trials of TAB treatment, demonstration of efficacy was extended to a longer duration than previously examined and to patients residing in rural communities.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03420313<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.31910","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:34:18Z","timestamp":1695828858000},"page":"e2331910","source":"Crossref","is-referenced-by-count":3,"title":["Technology-Assisted Buprenorphine Treatment in Rural and Nonrural Settings"],"prefix":"10.1001","volume":"6","author":[{"given":"Stacey C.","family":"Sigmon","sequence":"first","affiliation":[{"name":"Vermont Center on Behavior and Health, University of Vermont, Burlington"},{"name":"Department of Psychiatry, University of Vermont, Burlington"},{"name":"Department of Psychological Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly R.","family":"Peck","sequence":"additional","affiliation":[{"name":"Vermont Center on Behavior and Health, University of Vermont, Burlington"},{"name":"Department of Psychiatry, University of Vermont, Burlington"},{"name":"Department of Psychological Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney R.","family":"Batchelder","sequence":"additional","affiliation":[{"name":"Vermont Center on Behavior and Health, University of Vermont, Burlington"},{"name":"Department of Psychiatry, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Badger","sequence":"additional","affiliation":[{"name":"Department of Medical Biostatistics, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Heil","sequence":"additional","affiliation":[{"name":"Vermont Center on Behavior and Health, University of Vermont, Burlington"},{"name":"Department of Psychiatry, University of Vermont, Burlington"},{"name":"Department of Psychological Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Higgins","sequence":"additional","affiliation":[{"name":"Vermont Center on Behavior and Health, University of Vermont, Burlington"},{"name":"Department of Psychiatry, University of Vermont, Burlington"},{"name":"Department of Psychological Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"2","key":"zoi230925r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0217","article-title":"The burden of opioid-related mortality in the United States.","volume":"1","author":"Gomes","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"15","key":"zoi230925r2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.15585\/mmwr.mm7015a1","article-title":"State-level economic costs of opioid use disorder and fatal opioid overdose\u2014United States, 2017.","volume":"70","author":"Luo","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi230925r3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ypmed.2018.04.023","article-title":"The U.S. opioid epidemic: one disease, diverging tales.","volume":"112","author":"McBain","year":"2018","journal-title":"Prev Med"},{"issue":"10118","key":"zoi230925r4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0140-6736(17)32893-3","article-title":"Medications for opioid use disorder: bridging the gap in care.","volume":"391","author":"Volkow","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"zoi230925r5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities.","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"2","key":"zoi230925r7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi230925r8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0376-8716(03)00054-1","article-title":"Foreword to: buprenorphine and buprenorphine\/naloxone: a guide for clinicians.","volume":"70","author":"Fudala","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi230925r9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jval.2020.08.2098","article-title":"Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: a US nationwide small area analysis.","volume":"24","author":"Amiri","year":"2021","journal-title":"Value Health"},{"issue":"8","key":"zoi230925r10","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment.","volume":"105","author":"Jones","year":"2015","journal-title":"Am J Public Health"},{"issue":"1","key":"zoi230925r11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jrh.2018.34.issue-1","article-title":"Medication-assisted opioid treatment prescribers in federally qualified health centers: capacity lags in rural areas.","volume":"34","author":"Jones","year":"2018","journal-title":"J Rural Health"},{"issue":"4","key":"zoi230925r12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","article-title":"Access to treatment for opioid dependence in rural America: challenges and future directions.","volume":"71","author":"Sigmon","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"zoi230925r13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2014.2421","article-title":"The untapped potential of office-based buprenorphine treatment.","volume":"72","author":"Sigmon","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi230925r14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/jrh.v38.1","article-title":"Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder.","volume":"38","author":"Andrilla","year":"2022","journal-title":"J Rural Health"},{"issue":"1-3","key":"zoi230925r15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.drugalcdep.2011.10.016","article-title":"The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.","volume":"123","author":"Stein","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"zoi230925r16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1370\/afm.2099","article-title":"Barriers rural physicians face prescribing buprenorphine for opioid use disorder.","volume":"15","author":"Andrilla","year":"2017","journal-title":"Ann Fam Med"},{"issue":"6","key":"zoi230925r17","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.amepre.2018.02.006","article-title":"Prescribing practices of rural physicians waivered to prescribe buprenorphine.","volume":"54","author":"Andrilla","year":"2018","journal-title":"Am J Prev Med"},{"issue":"3","key":"zoi230925r18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/ADM.0b013e318287cfc9","article-title":"Opiate-dependent patients on a waiting list for methadone maintenance treatment are at high risk for mortality until treatment entry.","volume":"7","author":"Peles","year":"2013","journal-title":"J Addict Med"},{"issue":"4","key":"zoi230925r19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jsat.2009.04.002","article-title":"Scaling-up interim methadone maintenance: treatment for 1,000 heroin-addicted individuals.","volume":"37","author":"Schwartz","year":"2009","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"zoi230925r20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.drugalcdep.2009.03.007","article-title":"Interim methadone treatment: impact on arrests.","volume":"103","author":"Schwartz","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"zoi230925r21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ypmed.2015.04.017","article-title":"Interim treatment: bridging delays to opioid treatment access.","volume":"80","author":"Sigmon","year":"2015","journal-title":"Prev Med"},{"issue":"1","key":"zoi230925r22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1001\/archpsyc.63.1.102","article-title":"A randomized controlled trial of interim methadone maintenance.","volume":"63","author":"Schwartz","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"zoi230925r23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.addbeh.2015.07.030","article-title":"Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.","volume":"51","author":"Sigmon","year":"2015","journal-title":"Addict Behav"},{"issue":"2","key":"zoi230925r24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s13181-010-0080-z","article-title":"Wireless technologies, ubiquitous computing and mobile health: application to drug abuse treatment and compliance with HIV therapies.","volume":"6","author":"Boyer","year":"2010","journal-title":"J Med Toxicol"},{"issue":"5","key":"zoi230925r25","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.2430","article-title":"Mapping mHealth research: a decade of evolution.","volume":"15","author":"Fiordelli","year":"2013","journal-title":"J Med Internet Res"},{"issue":"1","key":"zoi230925r26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001363","article-title":"The effectiveness of mobile-health technologies to improve health care service delivery processes: a systematic review and meta-analysis.","volume":"10","author":"Free","year":"2013","journal-title":"PLoS Med"},{"issue":"2","key":"zoi230925r27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s13142-017-0492-2","article-title":"A systematic review of smartphone applications for smoking cessation.","volume":"7","author":"Haskins","year":"2017","journal-title":"Transl Behav Med"},{"issue":"25","key":"zoi230925r28","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMc1610047","article-title":"Interim buprenorphine vs. waiting list for opioid dependence.","volume":"375","author":"Sigmon","year":"2016","journal-title":"N Engl J Med"},{"key":"zoi230925r29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.drugalcdep.2018.05.032","article-title":"A novel mHealth application for improving HIV and hepatitis C knowledge in individuals with opioid use disorder: a pilot study.","volume":"190","author":"Ochalek","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"zoi230925r35","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1001\/archpsyc.62.10.1157","article-title":"Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.","volume":"62","author":"Marsch","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"zoi230925r36","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.drugalcdep.2013.08.007","article-title":"Characterizing and improving HIV and hepatitis knowledge among primary prescription opioid abusers.","volume":"133","author":"Dunn","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"zoi230925r37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/ADM.0000000000000235","article-title":"Brief Opioid Overdose Knowledge (BOOK): a questionnaire to assess overdose knowledge in individuals who use illicit or prescribed opioids.","volume":"10","author":"Dunn","year":"2016","journal-title":"J Addict Med"},{"issue":"2","key":"zoi230925r39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/add.1988.83.issue-2","article-title":"Assessment of opioid dependence with naloxone.","volume":"83","author":"Peachey","year":"1988","journal-title":"Br J Addict"},{"key":"zoi230925r43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2016.08.006","article-title":"Opioid overdose experience, risk behaviors, and knowledge in drug users from rural versus urban settings.","volume":"71","author":"Dunn","year":"2016","journal-title":"J Subst Abuse Treat"},{"key":"zoi230925r44","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.drugalcdep.2016.12.003","article-title":"Randomized controlled trial of a computerized opioid overdose education intervention.","volume":"173","author":"Dunn","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi230925r45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jsat.2012.12.011","article-title":"The Recovery Line: a pilot trial of automated, telephone-based treatment for continued drug use in methadone maintenance.","volume":"45","author":"Moore","year":"2013","journal-title":"J Subst Abuse Treat"},{"issue":"11","key":"zoi230925r46","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1007\/s10461-016-1637-x","article-title":"Examining the acceptability of mHealth technology in HIV prevention among high-risk drug users in treatment.","volume":"21","author":"Shrestha","year":"2017","journal-title":"AIDS Behav"},{"issue":"2","key":"zoi230925r47","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jsat.2006.04.002","article-title":"Behavioral HIV risk reduction among people who inject drugs: meta-analytic evidence of efficacy.","volume":"31","author":"Copenhaver","year":"2006","journal-title":"J Subst Abuse Treat"},{"issue":"7","key":"zoi230925r48","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s10461-017-1755-0","article-title":"A systematic review and meta-analysis of psychosocial interventions to reduce drug and sexual blood borne virus risk behaviours among people who inject drugs.","volume":"21","author":"Gilchrist","year":"2017","journal-title":"AIDS Behav"},{"issue":"1","key":"zoi230925r49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users.","volume":"2010","author":"Meader","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"zoi230925r50","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.cgh.2013.04.024","article-title":"Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review.","volume":"11","author":"Shah","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"zoi230925r31","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"zoi230925r32","first-page":"86","volume-title":"Methadone Treatment for Opiate Dependence","author":"Stitzer","year":"1999"},{"key":"zoi230925r33","volume-title":"Beck Anxiety Inventory Manual","author":"Beck","year":"1993"},{"key":"zoi230925r34","volume-title":"Manual for the Beck Depression Inventory\u2013II","author":"Beck","year":"1996"},{"key":"zoi230925r38","author":"Sobell","year":"1992"},{"key":"zoi230925r42","first-page":"99","volume-title":"Clinical Trials: Issues and Approaches","author":"Armitage","year":"1983"},{"key":"zoi230925r6","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2021 National Survey on Drug Use and Health. Accessed April 24, 2023. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt39443\/2021NSDUHFFRRev010323.pdf"},{"key":"zoi230925r30","unstructured":"US Census Bureau. 2010 Census Urban and Rural Classification and Urban Area Criteria. Accessed April 24, 2023. https:\/\/www.census.gov\/programs-surveys\/geography\/guidance\/geo-areas\/urban-rural\/2010-urban-rural.html"},{"key":"zoi230925r40","unstructured":"US Department of Health and Human Services. HIV basics. Accessed April 24, 2023. https:\/\/www.hiv.gov\/hiv-basics"},{"key":"zoi230925r41","unstructured":"The Foundation for AIDS Research. What is hepatitis C and how is it diagnosed? Accessed April 24, 2023. https:\/\/www.youtube.com\/watch?v=s6uRcp-2VfI"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2809950\/sigmon_2023_oi_230925_1695236269.85154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:34:24Z","timestamp":1695828864000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2809950"}},"subtitle":["Two Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.31910","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}